WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will present at two investor conferences next week. A live webcast of each presentation will be available through the “Investor Information” section of the Company’s website, www.immunogen.com; a replay of each presentation will be available at the same location for one week.
- The 13th Annual BIO CEO & Investor Conference
10:30 a.m. ET on February 15, 2011 in New York, NY
Presenter: Daniel Junius, President and CEO
- Leerink Swann Hot Topics in Therapeutics Roundtable Conference
9:55 a.m. ET on February 16, 2011 in New York, NY
Presenter: Gregory Perry, Senior Vice President and CFO
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen’s collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at www.immunogen.com.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology General Health